Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database.

BMC Health Serv Res · 2021 · PMC8590350 · PMID 34774053

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

The rate of in-patient hospitalization turned out to be quite significant for both drugs: 27% for infliximab and 17% for adalimumab.

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.